AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37491216 — intervention group
Group type: COMPARATOR
Intervention: In-person crisis prevention and intervention services (all components delivered in-person)
Number of subjects: 500
Study 37491235 — intervention group
Group type: EXPERIMENTAL
Intervention: Current coffee consumers
Number of subjects: 213
Study 37491235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cups of coffee consumed per day
Number of subjects: 213
Study 37491235 — intervention group
Group type: EXPERIMENTAL
Intervention: Current coffee consumption
Number of subjects: 213
Study 37491235 — intervention group
Group type: COMPARATOR
Intervention: Former and never coffee consumers
Number of subjects: 213
Study 37491264 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based contact management with TPT initiation
Number of subjects: 0
Study 37491264 — intervention group
Group type: COMPARATOR
Intervention: Facility-based contact management
Number of subjects: 0
Study 37491309 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 (4 mg) and TAK-117 (200 mg) orally each day for 3 days followed by 4 days off, weekly, until disease progression (PD)
Number of subjects: 10
Study 37491309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2) and nab paclitaxel therapy post PIKTOR
Number of subjects: 10
Study 37491373 — intervention group
Group type: EXPERIMENTAL
Intervention: MOv18 IgE antibody (dose escalation from 70 μg to 12 mg)
Number of subjects: 0
Study 37491373 — intervention group
Group type: EXPERIMENTAL
Intervention: MOv18 IgE antibody
Number of subjects: 0
Study 37491482 — intervention group
Group type: EXPERIMENTAL
Intervention: miR ratios (miR-199a-3p_let-7a-5p, miR-26b-5p_miR-142-5p, let-7b-5p_miR-19b-3p, miR-101-3p_miR-19b-3p, miR-93-5p_miR-19b-3p, let-7a-5p_miR-22-3p, miR-21-5p_miR-23a-3p) assessed by RT-qPCR
Number of subjects: 131
Study 37491482 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI), menopausal status (MS), interaction term BMI*MS, life-style score, breast density
Number of subjects: 131
Study 37491482 — intervention group
Group type: COMPARATOR
Intervention: Control group (66 controls)
Number of subjects: 131
Study 37491568 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA treatment
Number of subjects: 40
Study 37491568 — intervention group
Group type: COMPARATOR
Intervention: No OSA treatment or discontinued treatment
Number of subjects: 40
Study 37491619 — intervention group
Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 60
Study 37491619 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 60
Study 37491693 — intervention group
Group type: EXPERIMENTAL
Intervention: LFLG-pEF AS patients without atrial fibrillation (AF)
Number of subjects: 444
Study 37491693 — intervention group
Group type: EXPERIMENTAL
Intervention: LFLG-pEF AS patients with atrial fibrillation (AF)
Number of subjects: 444
Study 37491693 — intervention group
Group type: EXPERIMENTAL
Intervention: LFLG-pEF AS patients with AF
Number of subjects: 444
Study 37491693 — intervention group
Group type: COMPARATOR
Intervention: LFLG-pEF AS patients without AF
Number of subjects: 444
Study 37491889 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin + ATR inhibitor berzosertib
Number of subjects: 0
Study 37491889 — intervention group
Group type: COMPARATOR
Intervention: Lurbinectedin
Number of subjects: 0
Study 37491889 — intervention group
Group type: EXPERIMENTAL
Intervention: ATR inhibition
Number of subjects: 0
Study 37491889 — intervention group
Group type: COMPARATOR
Intervention: High CDKN1A/p21 expression
Number of subjects: 0
Study 37491889 — intervention group
Group type: COMPARATOR
Intervention: Increased levels of ERCC5/XPG
Number of subjects: 0
Study 37491889 — intervention group
Group type: COMPARATOR
Intervention: MYC-driven non-neuroendocrine tumors
Number of subjects: 0
Study 37491938 — intervention group
Group type: EXPERIMENTAL
Intervention: zuranolone 50 mg/day
Number of subjects: 196
Study 37491938 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 196
Study 37492067 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 12
Study 37492087 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiangli Dingxuan tablet combined with amlodipine besylate
Number of subjects: 0
Study 37492087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37492633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paclitaxel (oPAC) with encequidar (E) administered at 205 mg/m
Number of subjects: 28
Study 37492635 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly reminders
Number of subjects: 26
Study 37492635 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 26
Study 37492673 — intervention group
Group type: EXPERIMENTAL
Intervention: Confounder-adjusted MRI features
Number of subjects: 646
Study 37492673 — intervention group
Group type: EXPERIMENTAL
Intervention: GBM models from confounder-adjusted volumetric MRI features
Number of subjects: 646
Study 37492907 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient baths at 2 months
Number of subjects: 1505
Study 37492907 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient baths and frequent emollient application at 2 months
Number of subjects: 1505
Study 37492920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab 24 mg
Number of subjects: 49
Study 37492920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab 120 mg
Number of subjects: 49
Study 37492920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 37492970 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy with successful reperfusion (Thrombolysis in Cerebral Infarction score, 2b/3)
Number of subjects: 348
Study 37492970 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy with successful reperfusion at attempts 1
Number of subjects: 348
Study 37492970 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy with >2 recanalization attempts
Number of subjects: 348
Study 37492976 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA co-treatment
Number of subjects: 0
Study 37492976 — intervention group
Group type: COMPARATOR
Intervention: Vedolizumab without 5-ASA
Number of subjects: 0
Study 37493020 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy for <12 months
Number of subjects: 7159
Study 37493020 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy for 12 to <24 months
Number of subjects: 7159
Study 37493020 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy for 24 to <36 months
Number of subjects: 7159
Study 37493020 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker therapy for ≥36 months
Number of subjects: 7159
Study 37493020 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy for <36 months
Number of subjects: 7159
Study 37493095 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 11156
Study 37493229 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal probiotic suppository
Number of subjects: 147
Study 37493229 — intervention group
Group type: COMPARATOR
Intervention: Without vaginal probiotic suppository (Control)
Number of subjects: 147
Study 37493253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling resistance reduction
Number of subjects: 0
Study 37493253 — intervention group
Group type: EXPERIMENTAL
Intervention: Propulsion training
Number of subjects: 0
Study 37493269 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV/6120/ΔNS2/1030s vaccine (105 PFU)
Number of subjects: 30
Study 37493269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 37493287 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 50
Study 37493287 — intervention group
Group type: COMPARATOR
Intervention: Sham injections (sodium chloride 0.9%)
Number of subjects: 50
Study 37493538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal procedures
Number of subjects: 6705
Study 37493538 — intervention group
Group type: COMPARATOR
Intervention: Sacral colpopexy
Number of subjects: 6705
Study 37493538 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal mesh
Number of subjects: 6705
Study 37493538 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 6705
Study 37493538 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysteropexy
Number of subjects: 6705
Study 37493538 — intervention group
Group type: COMPARATOR
Intervention: Absorbable sutures
Number of subjects: 6705
Study 37493673 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital microscope (NGENUITY 3D visualisation system)
Number of subjects: 128
Study 37493673 — intervention group
Group type: COMPARATOR
Intervention: Conventional microscope
Number of subjects: 128
Study 37493759 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 186
Study 37493759 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Exercise (AER)
Number of subjects: 186
Study 37493759 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Training (COMB)
Number of subjects: 186
Study 37493898 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention for lowering high blood pressure (non-pharmacological, based on Disease Control Priorities)
Number of subjects: 240
Study 37493898 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 240
Study 37493932 — intervention group
Group type: EXPERIMENTAL
Intervention: MedViewer (MV) intervention providing real-time adherence feedback using IR-MALDESI mass spectrometry imaging of daily ART concentrations in hair.
Number of subjects: 36
Study 37494014 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide, 3.0 mg, once daily
Number of subjects: 70
Study 37494014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 37494051 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive dashboard-directed telehealth clinics
Number of subjects: 300
Study 37494051 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 37494101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (1 mg/kg) as an adjunct to sedation protocol
Number of subjects: 66
Study 37494101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 mcg/kg) and midazolam (2 mg)
Number of subjects: 66
Study 37494103 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling approaches (high-intensity and low-intensity) delivered remotely by phone or video call
Number of subjects: 19
Study 37494103 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling approaches (high-intensity and low-intensity)
Number of subjects: 19
Study 37494106 — intervention group
Group type: EXPERIMENTAL
Intervention: App-delivered socioemotional intervention (Affect Dyad)
Number of subjects: 218
Study 37494106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based training
Number of subjects: 218
Study 37494106 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (received socioemotional training after postintervention assessment)
Number of subjects: 218
Study 37494112 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-powered doctor
Number of subjects: 64
Study 37494112 — intervention group
Group type: COMPARATOR
Intervention: Human-controlled doctor
Number of subjects: 64
Study 37494277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue fibrocytes
Number of subjects: 0
Study 37494306 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program (CHP)
Number of subjects: 186
Study 37494485 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-994 30 mg
Number of subjects: 73
Study 37494485 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-994 90 mg
Number of subjects: 73
Study 37494485 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-994 180 mg
Number of subjects: 73
Study 37494485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 37494586 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically Integrated Breastfeeding Peer Counseling (ci-BPC)
Number of subjects: 720
Study 37494942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir Alafenamide (25 mg)
Number of subjects: 243
Study 37494942 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir (50 mg), Emtricitabine (200 mg), Tenofovir Disoproxil Fumarate (300 mg)
Number of subjects: 243
Study 37495019 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA supplementation for 95 days
Number of subjects: 52
Study 37495019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 37495197 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep artificial neural networks (DNNs) with data augmentation strategies
Number of subjects: 0
Study 37495197 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern DNNs using augmentation
Number of subjects: 0
Study 37495197 — intervention group
Group type: EXPERIMENTAL
Intervention: U-Nets and vision transformers
Number of subjects: 0
Study 37495274 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD)
Number of subjects: 1643
Study 37495276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination lipid-lowering therapy (rosuvastatin 10 mg plus ezetimibe 10 mg)
Number of subjects: 72050
Study 37495276 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin monotherapy (rosuvastatin 20 mg)
Number of subjects: 72050
Study 37495350 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS guidance by experienced operators
Number of subjects: 6005
Study 37495350 — intervention group
Group type: COMPARATOR
Intervention: IVUS guidance by less experienced operators
Number of subjects: 6005
Study 37495352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-Coated Balloon (SCB)
Number of subjects: 2123
Study 37495352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-Coated Balloon (SCB) in ISR cohort
Number of subjects: 2123
Study 37495367 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate and propionate supplementation in a murine model of emphysema
Number of subjects: 26
Study 37495367 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate supplementation
Number of subjects: 26
Study 37495367 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic smokers
Number of subjects: 26
Study 37495367 — intervention group
Group type: COMPARATOR
Intervention: Smokers with emphysema
Number of subjects: 26
Study 37495367 — intervention group
Group type: COMPARATOR
Intervention: Comparison of microbiome and metabolome
Number of subjects: 26
Study 37495367 — intervention group
Group type: COMPARATOR
Intervention: Higher acetate level in emphysema group
Number of subjects: 26
Study 37495797 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 758
Study 37495797 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 758
Study 37495797 — intervention group
Group type: EXPERIMENTAL
Intervention: DCB
Number of subjects: 758
Study 37495797 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 758
Study 37496001 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care program including training for staff and on-site specialty consultations
Number of subjects: 16
Study 37496001 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care attitudes and practices assessed through surveys of nursing home staff
Number of subjects: 16
Study 37496001 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative implementation data including fidelity assessments and interviews with Palliative Care Leads
Number of subjects: 16
Study 37496004 — intervention group
Group type: EXPERIMENTAL
Intervention: Afamelanotide 16 mg implants administered subcutaneously on Day 0, Day 1, and repeated on Day 7 and Day 8 if not well recovered.
Number of subjects: 6
Study 37496004 — intervention group
Group type: EXPERIMENTAL
Intervention: Afamelanotide 16 mg implants administered subcutaneously.
Number of subjects: 6
Study 37496117 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic regional perfusion (NRP)
Number of subjects: 0
Study 37496117 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine perfusion
Number of subjects: 0
Study 37496117 — intervention group
Group type: EXPERIMENTAL
Intervention: Viability testing of extended criteria donors
Number of subjects: 0
Study 37496117 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative strategies including machine perfusion
Number of subjects: 0
Study 37496117 — intervention group
Group type: COMPARATOR
Intervention: Rapid controlled DCD recovery
Number of subjects: 0
Study 37496298 — intervention group
Group type: EXPERIMENTAL
Intervention: parsaclisib 20 mg once daily for 8 weeks, followed by 20 mg once weekly thereafter, in combination with obinutuzumab and bendamustine
Number of subjects: 26
Study 37496366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV)
Number of subjects: 0
Study 37496394 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person grocery shopping
Number of subjects: 65
Study 37496394 — intervention group
Group type: EXPERIMENTAL
Intervention: Shopping online
Number of subjects: 65
Study 37496394 — intervention group
Group type: EXPERIMENTAL
Intervention: Shopping online with 'default' carts
Number of subjects: 65
Study 37496394 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-friendly recipes via email
Number of subjects: 65
Study 37496394 — intervention group
Group type: EXPERIMENTAL
Intervention: Default cart items acceptance
Number of subjects: 65
Study 37496394 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 65
Study 37496411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs)
Number of subjects: 13
Study 37496452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nalmefene (2.7 mg in 0.1 mL)
Number of subjects: 0
Study 37496452 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular nalmefene (1 mg)
Number of subjects: 0
Study 37496452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nalmefene (1 spray in each nostril and 2 sprays in the same nostril)
Number of subjects: 0
Study 37496612 — intervention group
Group type: EXPERIMENTAL
Intervention: Adintrevimab (300 mg intramuscular injection)
Number of subjects: 2582
Study 37496612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2582
Study 37497167 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral treprostinil initiated at 2 ng/kg/min intravenously or subcutaneously, with up-titration determined by clinicians
Number of subjects: 0
Study 37497167 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid cross-titration in an inpatient setting (median: 2 days)
Number of subjects: 0
Study 37497167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual cross-titration in an outpatient setting (median: 5 days)
Number of subjects: 0
Study 37497337 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS-High (IRS-H)
Number of subjects: 352
Study 37497337 — intervention group
Group type: COMPARATOR
Intervention: IRS-Low (IRS-L)
Number of subjects: 352
Study 37497337 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS-Ultra-Low (IRS-UL) with chemotherapy
Number of subjects: 352
Study 37497337 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS-H with anti-PD-(L)1
Number of subjects: 352
Study 37497337 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS
Number of subjects: 352
Study 37497354 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based cognitive behavioral therapy (FCBT)
Number of subjects: 128
Study 37497354 — intervention group
Group type: COMPARATOR
Intervention: Family-based psychoeducation and relaxation training (FPRT)
Number of subjects: 128
Study 37497354 — intervention group
Group type: EXPERIMENTAL
Intervention: FCBT
Number of subjects: 128
Study 37497354 — intervention group
Group type: COMPARATOR
Intervention: FPRT
Number of subjects: 128
Study 37497354 — intervention group
Group type: EXPERIMENTAL
Intervention: FCBT and FPRT
Number of subjects: 128
Study 37497372 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) over the primary motor cortex (M1), 10 daily sessions of 20 minutes each.
Number of subjects: 25
Study 37497372 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 25
Study 37497372 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) over the primary motor cortex (M1) in higher-frequency migraine patients.
Number of subjects: 25
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins use (6.7% reported use, 2346 individuals)
Number of subjects: 35103
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose statins use (0.6% reported use, 212 individuals)
Number of subjects: 35103
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 60 years
Number of subjects: 35103
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in the Southern region
Number of subjects: 35103
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous diagnosis of myocardial infarction
Number of subjects: 35103
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 35103
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 35103
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidaemia
Number of subjects: 35103
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 35103
Study 37497398 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of anti-hypertensives
Number of subjects: 35103
Study 37497636 — intervention group
Group type: EXPERIMENTAL
Intervention: End-ischemic dual HOPE for at least 2 hours
Number of subjects: 104
Study 37497636 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 104
Study 37497636 — intervention group
Group type: EXPERIMENTAL
Intervention: End-ischemic dual HOPE for at least 2 hours (in case of donor risk index >1.70)
Number of subjects: 104
Study 37497636 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (SCS) (in case of donor risk index >1.70)
Number of subjects: 104